Navigation Links
Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
Date:8/29/2013

KANSAS CITY, Kan., Aug. 29, 2013 /PRNewswire/ -- Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it will host a Pet Therapeutics Primer and Product Update Event, to be held September 11, 2013, at the Four Seasons Hotel in Boston. 

The purpose of the event is to comprehensively lay out the pet therapeutics regulatory framework and to provide a detailed program-by-program update on Aratana's current pet therapeutic development programs.Event:Pet Therapeutics Primer & Product UpdateDate: Wednesday, September 11, 2013 Time: 6:00 – 7:30 p.m. (Eastern Time) Location:Parris Room; Four Seasons Hotel BostonThe event will be webcast live beginning with the company presentations at 6:30 p.m. Eastern Time, and will then be made available as an archive on the Aratana Therapeutics website at aratana.investorroom.com.

Program Agenda:
Dr. Steven St. Peter, President and Chief Executive Officer of Aratana Therapeutics, will provide a brief introduction to the Company and its pipeline of pet therapeutic product candidates.  He also will discuss Aratana's licensing and partnership strategy for expanding its development pipeline.

Dr. Linda Rhodes, Aratana's Chief Scientific Officer, will provide an overview of the regulatory framework at the FDA's Center for Veterinary Medicine; specifically, the three concurrent regulatory work-streams: safety, efficacy and manufacturing.  Dr. Rhodes also will discuss the mechanics of filing an administrative New Animal Drug Application (NADA) and the subsequent notification of approval. 

Dr. Ernst Heinen, Aratana's Head of Drug Development and Evaluation, will provide an in-depth development update for each of Aratana's current product candidates, each of which is being developed concurrently for both cats and dogs.  These include AT-001, the Company's EP4 antagonist for the treatment of pain; AT-002, its ghrelin agonist for treating inappetence; and AT-003, Aratana's liposomal bupivacaine injection for treating post-operative pain.

There will be an opportunity for Q&A after each session, during which Dr. Marie-Paul Lachaud, Aratana's Head of Drug Development in Europe; Tammy Newbold, Aratana's Vice President of Chemistry, Manufacturing and Controls; and Don Stitzenberg, Aratana's Vice President of Manufacturing, will also be available.

About Aratana Therapeutics
Aratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
4. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
5. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
6. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
7. Aratana to Participate in Leerink Swanns November Management Access Days
8. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
9. Echo Therapeutics Announces Management Changes
10. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
11. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... BANGALORE , February 21, 2017 ... Appropriate Technology for Adoption by Plastic Industry  ... STEER, ... and functionalise materials in the fields of plastics, pharmaceuticals, ... collaboration with Merck KGaA, Darmstadt, Germany ...
(Date:2/21/2017)... 21, 2017 ... new imaging solution that connects Lexmark multifunction printers (MFPs) ... the world,s leading scanning and indexing software solutions for ... hospitals to use a Lexmark MFP at the point ... workflow, helping facilities reach HIMSS Stage 7 ...
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
(Date:2/21/2017)... NJ (PRWEB) , ... February 21, 2017 , ... ... research and conference coverage in veterinary medicine, will be launching its first bi-monthly ... animal health and medicine, business and practice management, and One Health. , ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):